Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Shapiro, Geoffrey
Item TypeName
Academic Article The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Academic Article Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Academic Article Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
Academic Article Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.
Academic Article Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Academic Article Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Academic Article Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Academic Article The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Academic Article Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Academic Article A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Academic Article A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Academic Article Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Academic Article Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Concept Protein Kinase Inhibitors
Academic Article Aurora kinase inhibition as an anticancer strategy.
Academic Article A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Academic Article Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
Academic Article Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
Academic Article Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Academic Article Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Academic Article Targeting CDK4 and CDK6: From Discovery to Therapy.
Academic Article Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Academic Article CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Academic Article The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Academic Article Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.
Academic Article CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Academic Article Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.
Academic Article First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Academic Article RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.